What is the use of Ahabir Abiraterone Acetate 250 mg tablets

 Ahabir (Abiraterone Acetate) 250 mg tablets

 Ahabir (Abiraterone Acetate) 250 mg tablets is utilized in the treatment of prostate cancer. It is also employed to treat other ailments according to the physician. It is often used along in conjunction with other medications in combination chemotherapy.


Ahabir (Abiraterone Acetate) 250 mg tablets is not recommended to be taken with a full stomach. Consuming it in conjunction with food could cause adverse reactions. Your doctor will determine which dose is needed and the frequency you have to consume it. It will depend on the condition you're currently being treated for. It can alter from time to time. You must adhere to the dosage your physician has recommended. Doing it in the wrong manner or taking too much may result in severe adverse side consequences. It could take a few months or even weeks for you to feel or see the benefits. However, do not stop taking it unless you doctor advises you to.




The USE OF AABIR TABLET

Prostate cancer


ADVANTAGES OF AHABIR TABLET


In Prostate cancer

The Prostate gland, also known as the prostate gland, is walnut-sized gland that makes seminal fluid, a substance that feeds and transports male sperms. The most frequent sign for prostate cancer difficulty in urinary frequency, although sometimes there are no signs in any way.  Ahabir (Abiraterone Acetate) 250 mg tablets slows down or stop the growth of cancerous cells by reducing levels of testosterone (natural hormone found in males) in males. It also helps with getting rid of urine and allows people to go to the bathroom.


SIDE EFFECTS of AHABIR TABLET

The majority of side effects do not require medical attention, and will disappear once the body adapts the medication. Contact your physician if they persist or you're concerned about them.

Common negative side effects of Ahabir

Edema (swelling)

Vomiting

A decrease in potassium levels in blood

A decrease in white blood cell count

Fatigue

The liver enzymes are boosted

Anemia (low amount in red blood cells)

Urinary tract infection

Diarrhea


HOW TO USE AABIR TABLET

Use this medication at the dosage and duration prescribed by your physician. Inhale it all in one go. Don't crush, chew or break it. Ahabir Tablets are to be taken with a full stomach.


How AHABIR TABLET Works

Ahabir Tablet acts as an anticancer medicine. It prevents androgen (male hormone) production in men. It does this by blocking one enzyme (CYP17) which produces androgen. This is the way it slows the progression of prostate cancer.


What is the most affordable price for Ahabir (Abiraterone Acetate)?

Please contact us at +91 9953466646 or you can drop an email to us at sales@aarkpharma.com.



Important Disclaimer : The contents of this website are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Do not disregard professional medical advice or delay in seeking it because of something you have read on this website.


Comments

Post a Comment

Popular posts from this blog

Hertraz (Trastuzumab): Revolutionizing Breast Cancer Treatment

Image
 Hertraz (Trastuzumab): Revolutionizing Breast Cancer Treatment Introduction: Breast cancer is one of the most prevalent and life-threatening diseases affecting women worldwide. However, significant strides have been made in the field of oncology to develop targeted therapies that improve patient outcomes. Hertraz, a groundbreaking medication based on the monoclonal antibody trastuzumab, has emerged as a game-changer in the treatment of HER2-positive breast cancer. This blog explores the efficacy, benefits, and future prospects of Hertraz in revolutionizing breast cancer treatment. Understanding Hertraz: Hertraz is a therapeutic drug that harnesses the power of trastuzumab, a monoclonal antibody that specifically targets HER2-positive breast cancer cells. HER2-positive breast cancer is characterized by an overexpression of the HER2 protein, which promotes cancer cell growth. By binding to HER2 receptors, Hertraz inhibits the growth and spread of cancer cells while enhancing the effecti
Read more

Midostar-Midostaurin: A Promising Breakthrough in Cancer Treatment

Image
  Introduction: Cancer continues to be a formidable disease, affecting millions of lives worldwide. However, the field of oncology has witnessed significant advancements, leading to the development of targeted therapies that offer new hope for patients. One such breakthrough is Midostar-Midostaurin , a novel medication with immense potential in the treatment of certain types of cancers. In this blog post, we will explore the mechanism of action, clinical applications, and the future prospects of Midostar-Midostaurin. Understanding Midostar-Midostaurin: Midostar-Midostaurin belongs to a class of drugs known as kinase inhibitors. It specifically targets and inhibits certain enzymes called receptor tyrosine kinases, including FLT3 and KIT. These enzymes play a critical role in the growth and proliferation of cancer cells, particularly in acute myeloid leukemia (AML) and aggressive systemic mastocytosis (ASM). Clinical Applications: Acute Myeloid Leukemia (AML): AML is a fast-growing type
Read more

Direct to patient pharmacy

Image
 Making clinical preliminaries more tolerant-driven is among the many difficulties confronting the drug business. One technique for further developing the patient experience is by conveying concentrate taking drugs straightforwardly to patient homes, otherwise called Direct-to-Patient or DTP. Notwithstanding, the execution of Direct-to-Patient might appear to be unrealistic in a profoundly controlled industry where explicit guidelines or direction is missing or ambiguous. Moreover, Direct-to-Patient encounters can be conflicting by nation, preliminary, or helpful region.  Along these lines, in follow up to the peak blog entry, Developing a Guide for Patient-Centric Logistics - Get Involved1 a working together with a group of Direct-to-Patient Sponsors, Couriers, CROS, and QPs will, through a progression of web journals, distinguish a portion of the direct-to-patient models, share contemplations for building up a Direct-to-Patient program according to the partners' point of view and
Read more